

MODERNA INC.

ISIN: US60770K1079

WKN: 60770K107

Asset Class: Stock

Company

2024/05/17 22:00:00



Price

132.90

USD

Difference

0.17%(0.22)



Contact Details

MODERNA INC. Tel: +1-617-714-6500

-- Fax: +

325 Binney Street Web: <http://www.modernatx.com>02142 Cambridge E-mail: info@modernatx.com

Company Profile

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	10,325,000,000		13,431,000,000		16,071,000,000	
Common stock capital		0		0		0
Fixed assets	8,101,000,000		12,656,000,000		8,798,000,000	
Equity capital of a company		13,854,000,000		19,123,000,000		14,145,000,000
Cash and cash equivalents	2,924,000,000		3,205,000,000		6,848,000,000	
Accrued liabilities		0		0		0
Other assets	-		-		-	
Current liabilities		3,015,000,000		4,923,000,000		9,128,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		1,557,000,000		2,041,000,000		1,596,000,000
Different income		-		-		-
Other liabilities		339,000,000		808,000,000		691,000,000
Total assets	18,426,000,000	18,426,000,000	26,087,000,000	26,087,000,000	24,869,000,000	24,869,000,000

Balance notes

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	5,600	3,900	2,700
Equity ratio	75.19%	73.30%	56.88%
Debt-equity ratio	33.00%	36.42%	75.81%

Others

	2023	2022	2021
Tax Expense Rate	-19.58%	12.67%	8.15%

MODERNA INC.

ISIN: US60770K1079

WKN: 60770K107

Asset Class: Stock

Income statement

	2023	2022	2021
Turnover	6,840,000,000	19,109,000,000	18,413,000,000
Net income	-4,714,000,000	8,362,000,000	12,202,000,000
EBIT	-3,972,080,000	8,636,633,600	12,200,944,000
Operating income before taxes	-3,942,000,000	9,575,000,000	13,285,000,000
Cash Flow	-3,118,000,000	4,981,000,000	13,620,000,000
Net interest income	383,000,000	171,000,000	0
Research and development expenses	4,224,000,000	2,947,000,000	1,759,000,000
Income taxes	772,000,000	1,213,000,000	1,083,000,000
Result from investments in subsidiaries, associates and other	-	-	0
Revenues per employee	1,121,760	4,499,925	6,263,148

Board of Directors

Members of Management Board

Noubar Afeyan	Chairman of Board of Directors
Elizabeth Nabel	Member of Board of Directors
Francois Nader	Member of Board of Directors
Robert Langer	Member of Board of Directors
Sandra Horning	Member of Board of Directors
Elizabeth Tallett	Member of Board of Directors
Paul Sagan	Member of Board of Directors
Stephen Berenson	Member of Board of Directors
Stéphane Bancel	Chairman of Managing Board
Brad Miller	Member of Executive Committee
Jamey Mock	Member of Executive Committee
Jerh Collins	Member of Executive Committee
Kate Cronin	Member of Executive Committee
Shannon Thyme Klinger	Member of Executive Committee
Stephen Hoge	Member of Executive Committee
Tracey Franklin	Member of Executive Committee